Previous surveillance

Three-year surveillance was carried out in 2012. New evidence was found in the areas of antidiarrhoeal agents and probiotics; however, this was considered insufficient to update at the time. The guideline was added to the static list in 2014.

Related NICE guidance

Since the publication of NICE guideline CG84 in April 2009, there have been related NICE guidelines published, which should be considered for cross-referencing to – these are detailed in the editorial amendments section.

Ongoing research

Five studies were assessed as having the potential to change recommendations; therefore, we plan to check the publication status regularly, and evaluate the impact of the results on current recommendations as quickly as possible. These studies are:

• Clinical study to evaluate the efficacy of probiotic product Bio-Kult Infantis as concomitant treatment of acute infectious diarrhoea in children
• Double blind clinical trial, controlled, randomized, phase IV, comparative of the effect of oral serum and racecadotril versus oral serum and placebo in children with acute diarrhoea
• Oral ondansetron vs domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial
• The effect of oral ondansetron on referral rate in children aged 6 months to 6 years attending in primary care out-of-hours service with acute gastroenteritis and vomiting
• The added effect of oral ondansetron to care-as-usual on persisting vomiting in children aged 6 months to 6 years, presenting at primary care out-of-hours service with acute gastroenteritis and concomitant vomiting

Views of topic experts

We sent questionnaires to 13 topic experts and received 7 responses. The topic experts either:

• participated in the guideline committee who developed the guideline
• were recruited to the NICE Centre for Guidelines Expert Advisers Panel to represent their specialty.

Overall, 4 felt that the guideline should be updated, 3 did not. One topic expert who felt that the guideline should be updated, highlighted a systematic review (Falszewska et al. 2018) about clinical dehydration assessment scales. The guideline currently uses a list of signs and symptoms to identify dehydration, as such further evidence in this area would be required before a change could be made.

One topic expert suggested that any reference to Escherichia coli (E. coli O157) should be replaced with verotoxin-producing E. coli (VTEC). We consulted with Public Health England (PHE) following limited feedback from stakeholders. PHE highlighted that although E. coli O157:H7 is a frequent cause of severe illness, other pathogenic non-O157-shiga toxin-producing E. coli (STEC) have been shown to cause the same range of symptoms as E. coli O157:H7, ranging from mild, non-bloody diarrheoa to more significant health outcomes, including heamolytic uraemic syndrome and death, especially in the young, the elderly or immunocompromised individuals. We have agreed to revise this recommendation in line with the PHE terminology on this subject.

Two topic experts suggested that ondansetron could be added to the recommendations because no anti-emetics are currently mentioned; however, the evidence found through surveillance continues to find an association between ondansetron and increased diarrhoea. Further evidence in this area is required before an impact on the guideline can be determined.

One topic expert highlighted a systematic review (Gordon and Akobeng 2016) regarding the effect of racecadotril on acute diarrhoea. A second topic expert highlighted European guidelines (Guarino et al. 2014), which currently recommend racecadotril. However, another topic expert commented that it represents an additional cost burden to the NHS that is not currently justified in the UK. The evidence found for racecadotril was inconclusive in terms of benefits as a treatment. We are monitoring 1 ongoing trial relating to racecadotril and will consider the results when available.

Views of stakeholders

Stakeholders are consulted on all surveillance decisions except if the whole guideline will be updated and replaced. Because this surveillance decision was to not update the guideline, we consulted on the decision.

Five stakeholders responded to our consultation; of these, 2 represented government organisations and 3 were professional bodies. One stakeholder agreed with the decision not to update the guideline, 1 disagreed and 3 did not state a response. One stakeholder highlighted the importance of viral diagnostics, which will be addressed by adding a cross-referral from the overview page of NICE guideline CG84 to the NICE diagnostics guidance on integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay), as detailed in the editorial amendments section.

Other sources of information

An RCT (Freedman et al. 2016) was identified from the topic issue log, which found that diluted apple juice was non-inferior to electrolyte maintenance solution in children aged 6 to 60 months with mild gastroenteritis and minimal dehydration. Because this RCT only looked at 1 brand/type of fruit juice, further evidence would be required before the recommendations on fruit juice would be amended.

See Appendix A for full details of stakeholders’ comments and our responses.

See ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual for more details on our consultation processes.